Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Using tissue cell culture to make a protein or polypeptide
Reexamination Certificate
2005-03-15
2008-09-02
Campell, Bruce (Department: 1648)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Using tissue cell culture to make a protein or polypeptide
C424S184100, C424S233100, C435S173900
Reexamination Certificate
active
07419808
ABSTRACT:
The present invention addresses the need to improve the yield of adenovirus when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of infection temperatures lower than 37° C. in a cell culture system results in improved yields of adenovirus. In addition, it has been demonstrated that when host cells are grow in a bioreactor, initiating adenovirus infection by diluting the host cells with fresh media and adenovirus results in improved yield of adenovirus. Methods of adenoviral production and purification using infection temperatures less than 37° C. are disclosed. Methods of adenoviral production and purification wherein the host cells are grown in a bioreactor and adenovirus infection is initiated by diluting the host cells with fresh media and adenovirus are also disclosed.
REFERENCES:
patent: 3962424 (1976-06-01), Zygraich et al.
patent: 4352883 (1982-10-01), Lim
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5824544 (1998-10-01), Armentano et al.
patent: 5932210 (1999-08-01), Gregory et al.
patent: 6190913 (2001-02-01), Singh
patent: 6194191 (2001-02-01), Zhang et al.
patent: 6355622 (2002-03-01), Fisher
patent: 6544788 (2003-04-01), Singh
patent: 7125706 (2006-10-01), Zhang et al.
patent: 2002/0177215 (2002-11-01), Zhang et al.
patent: 2002/0182723 (2002-12-01), Zhang et al.
patent: 2004/0106184 (2004-06-01), Senesac
patent: 2004/0229335 (2004-11-01), Zhang et al.
patent: 2005/0089999 (2005-04-01), Zhang et al.
patent: 2005/0287657 (2005-12-01), Blanche et al.
patent: 2006/0275781 (2006-12-01), Pham et al.
patent: 1244215 (2000-02-01), None
patent: WO 94/17178 (1994-08-01), None
patent: WO 98/00524 (1998-01-01), None
patent: WO 01/77304 (2001-10-01), None
Clontech Laboratories, Inc. Adeno-X™ Rapid Titer Kit Protocol-at-a-Glance (PT3651-2), published Jan. 3, 2002, 1 page.
Xie et al. Serum-Free Suspension Cultivation of PER.C6® Cells and Recombinant Adenovirus Production Under Different pH Conditions 2002, Biotechnology and Bioengineering, vol. 80 No. 5, pp. 571.
Zhang et al. Production of Adenoviral Vectors for Gene Therapy in Suspension Serum Free Cultures. Introgen Therapeutics, Inc. Presentation Posted at Wave Biotech, LLC. [online] in Mar. 2003 [Retrived Oct. 20, 2006], Retrived from the Internet:<URL: http://www.wavebiotech.com/products/wave—bioreactor/literature.html>.
Singh V., Disposable bioreactor for cell culture using wave-induced agitation, 1999, Cytotechnology, vol. 30, pp. 149-158.
Product information page for Wave Bioreactor System20, Posted at Wave Biotech, LLC. [Retrived Aug. 11, 2007], Retrived from the Internet:<URL: http://http://www.wavebiotech.com/products/wave—bioreactor/system20/index.html#>.
U.S. Appl. No. 60/406,591, filed Aug. 28, 2002, Senesac et al.
Aboud et al., “Rapid purification of extracellular and intracellular Moloney murine Leukemia virus,”Arch. Virol., 71:185-195, 1982.
Batra et al., “IκBα gene transfer is cytotoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis factor-α-mediated cell death,”Am. J. Respir. Cell Mol. Biol., 21(2):238-245, 1999.
Berg et al., “High-level expression of secreted proteins from cells adapted to serum-free suspension culture,”Biotechniques, 14(6):972-978, 1993.
Bett et al., “An efficient and flexible system for construction of adenovirus vectors with-insertions or deletions in early regions 1 and 3,”Proc. Natl. Acad. Sci., USA, 91:8802-8806, 1994.
Blackwell et al., “Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma,”Ach. Otolaryngol. Head. Neck Surg., 125(8):856-863, 1999.
Chillon et al., “Group D adenoviruses infect primary central nervous system cells more efficiently that those from group C,”J. Virol., 73(3):2537-2540, 1999.
Chroboczek et al., “The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2,”Virology, 186:280-285, 1992.
Cristiano et al, “Viral and nonviral gene delivery vectors for cancer gene therapy,”Cancer Detect. Prev., 22(5):445-454, 1998.
Crooks et al., “Purification and analysis of infectious virions and native non-structural antigens from cells infected with tick-borne encephalitis virus,”J. Chromatogr., 502(1):59-68, 1990.
Dorai et al., “A recombinant defective adenoviral agent expressing anti-Bcl-2 ribozyme promotes apoptosis of Bcl-2-expressing human prostate cancer cells,”Int. J. Cancer, 82(6):846-852, 1999.
Engelhardt et al., “Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreased inflammatory response in mouse liver,”PNAS91:6196-6200, 1994.
Fathallah-Shaykh et al., “Gene Transfer of IFN-γ into Established Brain Tumors Represses Growth by Antiangiogenesis,”J of Immunology, 164:217-222, 2000.
Feldman et al., “Perspective of arterial gene therapy for the prevention of restenosis,”Cardiovasc. Res., 32(2):194-207, 1996.
Garnier et al., “Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells,”Cytotechnology, 15(1-3):145-155, 1994.
Gilbert, “Adaptation of cells to serum free culture for production of adenovirus vectors and recombinant proteins,”Williamsburg BioProcessing Conference, Nov. 18-21, 1996.
Goldstein et al, “Defective lipoprotein receptors and atherosclerosis—lessons from an animal counterpart of familial hypercholesterolemia,”New Engl. J. Med., 309(11983):288-296, 1983.
Graham and Prevec, “Manipulation of adenovirus vectors,” In:Methods in Molecular Biology: Gene Transfer and Expression Protocol, Murray (Ed.), Humana Press, Clifton, NJ, vol. 7: Chapter 11, pp. 109-127, 1991.
Graham and Prevec, “Methods for construction of adenovirus vectors,”Mol. Biotechnol., 3(3):207-220, 1995.
Graham et al., “Characteristics of a human cell line transformed by DNA from human adenovirus type 5,”J. Gen. Virol., 36(1):59-74, 1977.
Graham, “Growth of 293 cells in suspension culture,”J. Gen. Virol., 68(Pt 3):937-940, 1987.
Green et al., “A new scalable method for the purification of recombinant adenovirus vectors,”Human Gene Therapy, 13:1921-1934, 2002.
Han et al., “Receptor-mediated gene transfer to cells of hepatic origin by galactosylated albumin-polylysine complexes,”Biol. Pharm. Bull., 22(8):836-840, 1999.
Hermens and Verhaagen, “Viral vectors, tools for the gene transfer in the nervous system,”Prog. Neurobiol., 55(4):399-432, 1998.
Hollstein et al., “p53 mutations in human cancers,”Science, 253(5015):49-53, 1991.
Hurwitz et al., “Suicide gene therapy for treatment of retinoblastoma in a murine model,”Hum. Gene Ther., 10:441-448, 1999.
Huyghe et al., “Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography,”Human Gene Therapy, 6:1403-1416, 1995.
Irie et al., “Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer,”Antisense Nucleic Acid Drug Dev., 9(4):341-349, 1999.
Ishibashi et al, “Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery,”J. Clin. Invest., 92:883-893, 1993.
Ishibashi et al, “Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice,”J. Clin. Invest., 93:1885-1893, 1994.
Jardon and Garnier, “pH, pCO2, and temperature effect on r-adenovirus production,”Biotechnol Prog., 19(1):202-208, 2003.
Jiang et al., “The melanoma differentiation associated gene mda-7 suppresses cancer cell growth,”Proc. Nat'l Acad. Sci. USA, 93:9160-9165, 1996.
Jones and Shenk, “Isolation of deletion an
Pham Hai
Zhang Shuyuan
Blumel Benjamin P
Campell Bruce
Fulbright & Jaworski L.L.P.
Introgen Therapeutics Inc.
LandOfFree
Methods and compositions for the production of adenoviral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the production of adenoviral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the production of adenoviral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3974250